Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatmentMarket Watch • 12/22/23
WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosisPRNewsWire • 12/21/23
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedemaPRNewsWire • 12/18/23
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndromePRNewsWire • 11/11/23
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedemaPRNewsWire • 11/09/23
Ionis Pharmaceuticals (IONS) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/02/23
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 10/26/23
Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercializationPRNewsWire • 10/04/23
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefitPRNewsWire • 09/28/23
Strength Seen in Ionis Pharmaceuticals (IONS): Can Its 8.5% Jump Turn into More Strength?Zacks Investment Research • 09/27/23
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's diseasePRNewsWire • 09/27/23